Patents Assigned to Institute Pasteur
-
Patent number: 10018629Abstract: A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.Type: GrantFiled: August 8, 2014Date of Patent: July 10, 2018Assignees: INSTITUTE PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT-PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Marie-Lise Gougeon, Manuelle Viguier, Hervé Bachelez, Nicolas Fazilleau
-
Patent number: 8986936Abstract: The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.Type: GrantFiled: May 20, 2010Date of Patent: March 24, 2015Assignees: Inserm (Institut National de la Santa et de la Recherche Medicale), Institute Pasteur de Lille, Le Centre Hospitalier Regional Universitaire de Lille, Universite de RouenInventors: Florence Pinet, Paul Mulder, Christophe Bauters, Vincent Richard
-
Patent number: 8895725Abstract: Use of 9,10-anthraquinone compounds of formula (I) or pharmaceutical salts thereof or plant extracts containing said compounds in the preparation of anti-HCV medicaments is disclosed, in which Y1 are Y2 are independently hydrogen, hydroxyl or groups of formula (II); and R1, R2, R3, R4, R5 and R6 are independently hydrogen, hydroxyl, carboxyl, cyano group, nitro group, groups of formula (III) or groups selected from those substituted or unsubstituted groups: amino, C1-C6 aliphatic hydrocarbon, C3-C7 cyclic aliphatic hydrocarbon, C1-C6 alkoxy, C2-C7 carbalkoxy, C1-C4 acyloxy, C6-C20 aryl, or 5 to 7 members heterocyclic or benzoheterocyclic thereof; or R5 and R6 form the group of formula (IV). The compounds of present invention are cheap, safe and effective because that they mostly come from traditional Chinese medicines and have better anti-HCV effects and lighter side effects.Type: GrantFiled: November 23, 2009Date of Patent: November 25, 2014Assignees: Shanghai Institute of Pharmaceutical Industry, Institute Pasteur of Shanghai, Chinese Academy of SciencesInventors: Shuguang Wang, Jin Zhong, Deyun Kong, Jue Hu, Bo Li, Wen Gao, Chunyan Gai, Changlong Zhuang, Haitao Mao
-
Publication number: 20120165400Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.Type: ApplicationFiled: May 5, 2011Publication date: June 28, 2012Applicants: The Children's Medical Center Corporation, The Institute PasteurInventors: André Choulika, Richard C. Mulligan
-
Publication number: 20110224414Abstract: Use of 9,10-anthraquinone compounds of formula (I) or pharmaceutical salts thereof or plant extracts containing said compounds in the preparation of anti-HCV medicaments is disclosed, in which Y1 are Y2 are independently hydrogen, hydroxyl or groups of formula (II); and R1, R2, R3, R4, R5 and R6 are independently hydrogen, hydroxyl, carboxyl, cyano group, nitro group, groups of formula (III) or groups selected from those substituted or unsubstituted groups: amino, C1-C6 aliphatic hydrocarbon, C3-C7 cyclic aliphatic hydrocarbon, C1-C6 alkoxy, C2-C7 carbalkoxy, C1-C4 acyloxy, C6-C20 aryl, or 5 to 7 members heterocyclic or benzoheterocyclic thereof; or R5 and R6 form the group of formula (IV). The compounds of present invention are cheap, safe and effective, because that they mostly conic from traditional Chinese medicines and have better anti-HCV effects and lighter side effects.Type: ApplicationFiled: November 23, 2009Publication date: September 15, 2011Applicants: Shanghai Institute of Pharmaceutical Industry, Institute Pasteur of Shanghai, Chinese Academy of SciencesInventors: Shuguang Wang, Jin Zhong, Deyun Kong, Jue Hu, Bo Li, Wen Gao, Chunyan Gai, Changiong Zhuang, Haitao Mao
-
Patent number: 7960525Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.Type: GrantFiled: September 25, 2007Date of Patent: June 14, 2011Assignees: The Institute Pasteur, The Children's Medical Center CorporationInventors: André Choulika, Richard C. Mulligan
-
Publication number: 20100291586Abstract: Method for the diagnosis or the screening of an arbovirus infection and preferably a flaviviridae infection and more preferably a flavivirus infection, reagents useful in said method and their applications. Said method comprises: (i) contacting a sample from the subject or animal with a solid support sensitized with an Ig binding protein which is directed against a specific class of Ig molecules of the subject or animal species under consideration and (ii) incubating the immunocomplex formed in (i) with a detector molecule consisting of a hybrid protein comprising at least an arboviral ED3 domain and an alkaline phosphatase (PhoA), the detection of said immunocomplex being the sign of the presence of an arbovirus in said sample.Type: ApplicationFiled: June 13, 2008Publication date: November 18, 2010Applicants: INSTITUTE PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Hugues Bedouelle, Elodie Brient-Litzler, Philippe Dussart, Philippe Despres, Laetitia Bremand
-
Patent number: 7833699Abstract: The present invention concerns methods for in vitro detection of an infection by Mycobacterium tuberculosis in mammals, and methods for in vitro distinction between mammals infected with Mycobacterium tuberculosis in which the disease is declared (active form) and mammals which are infected but asymptomatic for tuberculosis (latent form), and a method for in vitro distinction between mammals presenting an active form of tuberculosis and mammals not infected by M. tuberculosis or presenting a latent form of tuberculosis. The present invention also pertains to kits for detection and distinction between infected mammals presenting tuberculosis symptoms and infected mammals with no disease development, and a kit for distinguishing between mammals presenting an active form of tuberculosis and mammals not infected by M. tuberculosis or presenting a latent form of tuberculosis.Type: GrantFiled: December 28, 2006Date of Patent: November 16, 2010Assignees: Institute Pasteur de Lille, Inserm (Institut National de la Sante Et de la Recherche Medicale), Universite Libre de Bruxelles, Universite du Droit Et de la Sante de Lille IIInventors: Camille Locht, Françoise Mascart, Stéphane Temmerman, Jean-Michel Hougardy, Sammy Place, Christian Sergheraert
-
Patent number: 7736850Abstract: The invention relates to a novel strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from a sample collected in Hanoi (Vietnam), reference number 031589, nucleic acid molecules originating from the genome of same, proteins and peptides coded by said nucleic acid molecules and, more specifically, protein N and the applications thereof, for example, as diagnostic reagents and/or as a vaccine.Type: GrantFiled: December 2, 2004Date of Patent: June 15, 2010Assignees: Institute Pasteur, Centre National de la Recherche Scientifique, Universite Paris 7Inventors: Sylvie Van Der Werf, Nicolas Escriou, Bernadette Crescenzo-Chaigne, Jean-Claude Manuguerra, Frederick Kunst, Benoît Callendret, Jean-Michel Betton, Valérie Lorin, Sylvie Gerbaud, Ana Maria Burguiere, Saliha Azebi, Pierre Charneau, Frédéric Tangy, Chantal Combredet, Jean-François Delagneau, Monique Martin
-
Publication number: 20100129371Abstract: The invention concerns a method for obtaining an antiserum directed against a proteinic toxin by administering to an animal a solution comprising a genetic construct encoding a toxin immunogenic fragment, then applying an electric field in the administering zone, and isolating the serum. The invention also concerns the antiserum obtainable by the method as well as the use of the solution for making a medicine for preventing or treating a toxic effect related to absorption by a mammal of a toxin. The invention is characterized in that said medicine is formulated to be administered by electrotransfer.Type: ApplicationFiled: July 28, 2006Publication date: May 27, 2010Applicants: Centre National de la Recherche Scientifique (CNRS), Institute Pasteur, Institute National de la Sante et de la Recherche Medicale (INSERM), Universite Rene DescartesInventors: Daniel Scherman, Pascal Bigey, Capucine Trollet, Michel R. Popoff, Yannick Pereira
-
Publication number: 20100008894Abstract: The invention relates to a complex formed between the 3?-phosphoadenosine 5?-phosphate and polypeptide in human cells, to the use of pAp or of a molecule which mimics pAp for modulating the activity of poly(ADP-ribose)polymerase and small fragment nuclease in human cells, and to process of screening a molecule as a candidate drug for the treatment of diseases where modulation of at least one of the metabolic activities modulated by pAp is needed such as bipolar disorder or related diseases.Type: ApplicationFiled: September 22, 2006Publication date: January 14, 2010Applicants: Institute pasteur, Centre National De Recherche Scientifique (CNRS)Inventors: Undine Mechold, Vasily Ogryzko, Antoine Danchin
-
Publication number: 20090246222Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.Type: ApplicationFiled: March 7, 2007Publication date: October 1, 2009Applicants: Institute Pasteur de Lille, Institute National de la Sante de la Recherche Medicale (Inserm)Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
-
Patent number: 7585656Abstract: The present invention provides the crystal structure of the Trypanosoma cruzi PRACA proline racemase. Methods of modelling drugs that treat or prevent infection by T. cruzi are also provided, as are the drugs that are identified.Type: GrantFiled: May 26, 2004Date of Patent: September 8, 2009Assignees: Institute Pasteur, Centre National de la Recherche Scientifique (CNRS)Inventors: Paola Minoprio, Pedro Alzari, Alejandro Buschiazzo, Christophe Grégoire, Armand Berneman, Wim M. Degrave
-
Publication number: 20090060896Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.Type: ApplicationFiled: September 25, 2007Publication date: March 5, 2009Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, THE INSTITUTE PASTEURInventors: Andre Choulika, Richard C. Mulligan
-
Patent number: 7476386Abstract: The invention concerns mixed micelles or micro-aggregates for inducing an immune response containing at least a first lipopeptide comprising a CTL epitope and at least a first lipid motif; and a second lipopeptide comprising at least an auxiliary T epitope and at least a lipid motif, whereof the type can be different from the first lipopeptide motif. Said micelles can be used as medicines and vaccines.Type: GrantFiled: December 2, 1998Date of Patent: January 13, 2009Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Centre National de la Recherche Scientifique, Institute Pasteur de LilleInventors: Hélène Gras-Masse, Marc Bossus, Guy Lippens, Jean-Michel Wieruszeski, André Tartar, Jean-Gérard Guillet, Isabelle Bourgault-Villada
-
Publication number: 20080242601Abstract: The present invention relates to polypeptides that inhibit the NF-&kgr; B signaling pathway and polynucleotides encoding the same. The present invention further provides methods for the modulation of and/or treatment of inflammatory responses, oncogenesis, viral infection; the regulation of cell proliferation and apoptosis; and regulation of B or T lymphocytes in antigenic stimulation, by administering the polypeptides of the present invention to a subject in need thereof. Finally, the present invention provides a method of identifying polypeptides that modulate oligomerization of NEMO.Type: ApplicationFiled: September 24, 2004Publication date: October 2, 2008Applicants: Institute Pasteur, Inserm (Inst.Nat.de la Sante et de la Rech.Med., CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Fabrice Agou, Gilles Courtois, Alain Israel, Michel Veron, Francois Traincard, Shoji Yamaoka, Yves-Marie Coic, Francoise Baleux
-
Patent number: 7285538Abstract: Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof.Type: GrantFiled: January 2, 2003Date of Patent: October 23, 2007Assignees: The Children's Medical Center Corporation, The Institute PasteurInventors: André Choulika, Richard C. Mulligan
-
Patent number: 7217801Abstract: DNA encoding core+1 polypeptides of hepatitis C virus (HCV), nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.Type: GrantFiled: September 17, 2003Date of Patent: May 15, 2007Assignees: Institute Pasteur, Hellenic Pasteur InstituteInventors: Penelope Mavromara, Agoritsa Varaklioto, Urania Georgopoulou
-
Publication number: 20070042448Abstract: Methods for identifying molecules which inhibit the virulence or pathogenicity of Helicobacter pylori by modulating the activity of hydrolases encoded by genes amiA, mltD and slt. Compositions and diagnostic and treatment methods using hydrolases and molecules which inhibit them.Type: ApplicationFiled: June 2, 2006Publication date: February 22, 2007Applicant: INSTITUTE PASTEURInventors: Ivo Boneca, Catherine Chaput
-
Patent number: 7030234Abstract: Retroviral strains of the non-M, non-O HIV-1 group, in particular a strain designated YBF30, its fragments and also its uses as a diagnostic reagent and as an immunogenic agent. The HIV-1 viruses which differ both from the M group and the O group exhibit the following characteristics: little or no serological reactivity with regard to the proteins of the M and O groups and strong serological reactivity with regard to the proteins which are derived from the strain YBF30 according to the invention or the strain CPZGAB SIV; absence of genomic amplification when using primers from the env and gag regions of the M and O HIV-1 groups; genomic amplification in the presence of primers which are derived from the YBF30 strain according to the invention; and homology of the products of the envelope gene which is greater than 70% with regard to the YBF30 strain.Type: GrantFiled: November 22, 2002Date of Patent: April 18, 2006Assignees: Institute National de la Sante et de la Recherche Medicale-Inserm, Assistance Publique-Hopitaux de Paris, Institute PasteurInventors: Phillippe Mauclere, Ibtissam Loussert-Ajaka, Francois Simon, Sentob Saragosti, Francoise Barre-Sinoussi